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Abstract
Background: Parkinsonian variant of multiple system atrophy is a neurodegenerative disorder frequently
misdiagnosed as Parkinson’s disease. No early imaging biomarkers currently differentiate these disorders.
Methods: Simple visual imaging analysis of the substantia nigra and locus coeruleus in neuromelanin-sensitive
magnetic resonance imaging and nigrosome 1 in susceptibility-weighted sequences was performed in thirty
patients with parkinsonian variant of multiple system atrophy fulfilling possible/probable second consensus
diagnostic criteria. The neuromelanin visual pattern was compared to patients with Parkinson’s disease with the
same disease duration (n = 10) and healthy controls (n = 10). Substantia nigra semi-automated neuromelanin area/
signal intensity was compared to the visual data.
Results: Groups were similar in age, sex, disease duration, and levodopa equivalent dose. Hoehn & Yahr stage was
higher in parkinsonian multiple system atrophy patients, 69% of whom had normal neuromelanin size/signal,
significantly different from Parkinson’s disease patients, and similar to controls. Nigrosome 1 signal was lost in 74%
of parkinsonian multiple system atrophy patients. Semi-automated neuromelanin substantia nigra signal, but not
area, measurements were able to differentiate groups.
Conclusions: In patients with parkinsonism, simple visual magnetic resonance imaging analysis showing normal
neuromelanin substantia nigra and locus coeruleus, combined with nigrosome 1 loss, allowed the distinction of the
parkinsonian variant of multiple system atrophy from Parkinson’s disease and healthy controls. This easy and widely
available method was superior to semi-automated measurements in identifying specific imaging changes in
substantia nigra and locus coeruleus.
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Background
Multiple system atrophy (MSA) is a sporadic, adult-onset
and rapidly progressive neurodegenerative disorder, involv-
ing striatonigral, olivopontocerebellar, pyramidal, and auto-
nomic systems. Clinical phenotypes are classified according
to the most prominent motor symptom as parkinsonian
(MSA-P) or cerebellar (MSA-C) [1].
The parkinsonian variant (MSA-P) has significant clin-
ical overlap with Parkinson’s disease (PD), leading to fre-
quent misdiagnosis [2], especially in the early stages, when
red flags may be absent [3]. A post mortem study of
neuropathologically-confirmed MSA-P showed that most
patients were initially clinically diagnosed as PD and in
half, the diagnosis was later changed to MSA [2].
Although less prevalent than PD, this devastating disorder
is an important differential diagnosis to consider when
evaluating a patient presenting with parkinsonism as there
are significant prognostic and therapeutic implications.
Substantia nigra (SN) and locus coeruleus (LC) are
dopaminergic and noradrenergic regions known to be
selectively affected in PD and MSA-P [4, 5]. New mag-
netic resonance imaging (MRI) sequences have been re-
cently developed, allowing the visualization of SN and
LC in vivo and correlating with neuronal loss and iron
deposition, two hallmarks of neurodegeneration [6–17].
Specific T1-weighted images show the SN and the LC
as high-intensity signal regions due to the paramagnetic
properties of neuromelanin (NM), a by-product of dopa-
mine and noradrenaline metabolism that physiologically
accumulates in neurons [6]. A specific pattern of NM
loss has been described in PD patients, with both quanti-
tative [7–9] and qualitative [10–12] methods. Few stud-
ies have used NM-MRI in MSA-P patients and the
findings were inconclusive [18–20].
Iron content can be studied with MRI-specific se-
quences such as susceptibility-weighted imaging (SWI).
A poor iron-binding region in the dorsolateral SN,
nigrosome 1 (N1), is visualized as a hyperintense signal
resembling a “swallow tail” in healthy individuals and its
loss has been shown in PD and other degenerative par-
kinsonisms [13–17], including in MSA [17].
Accurate and easy to use diagnostic tools that can dif-
ferentiate PD from MSA-P in early disease stages are
greatly needed in clinical practice.
This study aimed to analyze the NM imaging visual
pattern of the SN and LC in combination with the SWI
N1 signal in patients with MSA-P. To the best of our
knowledge, this is the first study in MSA-P patients
combining visual analysis of NM and N1 SWI images.
Methods
Study population and historical controls
MSA patients from Campus Neurológico Sénior were
identified from a movement disorders imaging database
and selected if a 3 T MRI with a devoted movement disor-
ders predefined protocol [6, 7] was performed. Clinical
characteristics were assessed by two movement disorders
specialists (RMS, ACC): disease duration since onset of
first symptom and since diagnosis, presenting symptom,
presence of cerebellar signs, Hoehn and Yahr stage [HY],
levodopa equivalent daily dose [LEDD]. Only patients with
parkinsonism and fulfilling second consensus criteria for
possible or probable MSA [1] were included. PD patients
with 2 to 5 years of disease duration (PD2_5y), and healthy
controls (HC), who were included in previous studies,
were selected to match disease duration in our study
population [7, 11, 21, 22]. The study was approved by the
local Ethical Committee and complied with national legis-
lation and the Declaration of Helsinki guidelines.
Imaging protocol
A NM and SWI MR protocol was performed using a 3.0
T Phillips scanner (Philips Achieva; Philips Medical Sys-
tems, Best, The Netherlands). The NM-sensitive pulse
sequence parameters were: T1-weighted fast spin-echo;
repetition time/effective echo time 633/10ms; echo train
length 3; number of slices 20; slice thickness 2.5 mm;
intersection gaps 0 mm; matrix size 548 × 474; field of
view 220mm (pixel size 0.40 × 0.40mm); acquisition
time 8min, adapted from the previous description by
Sasaki et al [6, 7]. Slices were set in an oblique axial
plane perpendicular to the fourth ventricle floor and
covering from the posterior commissure to the inferior
border of the pons, as previously described [6, 7].
The axial SWI sequence parameters were: repetition
time/effective echo time 14/20 ms, flip angle of 10, num-
ber of slices 200, thickness 1/0.99/1, plane matrix 512,
200 × 181, field of view 220mm. Phase images were
automatically filtered after acquisition, according to an
established algorithm [23].
3 T T1-weighted sagittal sequences, obtained using a
standard protocol with parameters used routinely in
clinical practice [24], were additionally performed for
morphometric brainstem analysis.
Image analysis
The following diagram (Fig. 1) summarizes the MRI im-
aging analyses that were performed.
Simple visual analysis
An experienced neuroradiologist (SR), blinded to the clin-
ical diagnosis, performed a simple visual analysis of NM-
sensitive MR images and SWI N1 signal.
Images were classified according to the presence of ar-
tifacts and their interference with the visual assessment
of the NM high signal. Only the images that allowed a
degree of confidence in evaluation that was equal to or
higher than 50% were considered. Two MSA-P patients’
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images had artifacts that interfered with the visual as-
sessment of the NM high signal (one for both SN and
LC, other for LC) (additional Table 1) and were ex-
cluded (degree of confidence in evaluation < 50%).
The SN size and signal intensity and the LC signal inten-
sity in NM-MRI were classified using a three-point scale: 1–
normal, 2–reduced, 3-absent. Both sides were rated inde-
pendently. When applicable, the most affected segment was
identified (1-lateral, 2-medial, 3-global) for each side.
Each participant was then classified as previously de-
scribed [11] into one of four groups: probable PD (SN
signal markedly reduced in size/ intensity in the lateral
area and asymmetrical); possible PD (SN signal reduced
in size/intensity and asymmetrical); not suggestive of PD
(SN signal normal in size/intensity and symmetrical); or
uncertain (not filling any of the previous descriptions).
The N1 image in SWI was categorized as 1-present or
2-absent for each side. SWI images were only available
for MSA-P patients.
Morphometrics
The T1-weighted sagittal 3 T images were used to calcu-
late brainstem metrics (midbrain area, pons area, middle
cerebellar peduncle width and superior cerebellar ped-
uncle width, III ventricle width, frontal horn width)
using previously described methods [25, 26]. Pons/mid-
brain ratio, parkinsonian index and parkinsonian index
version 2.0 were also calculated [25, 26].
Semi-automated imaging analysis
SN NM-sensitive images were additionally analyzed using
semi-automated measurements of the area and signal in-
tensity [contrast-to-ratio (CR) of SN internal and external
segments], as previously described [6, 7, 11, 21, 22].
Statistical analysis
The X2 test was used to compare the visual analysis re-
sults and ANOVA was used to compare the quantitative
measurements in the three groups. For quantitative mea-
surements with equal variances assumed, Bonferroni
multiple comparisons post hoc analysis were performed
to compare between the three groups. The t-test for in-
dependent samples was used to compare findings in
MSA-P and PD2_5y.
To compare the visual analysis results of SN size and
signal intensity with the semi-automated area and CR
Fig. 1 Imaging analysis and available sample size for each group and MRI modality
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measurements, each individual SN was considered. In
order to account for left/right differences in SN area and
CR measurements, an asymmetry index (lower value/
higher value) was calculated for area, CR internal seg-
ment and CR external segment for each subject. Differ-
ences in quantitative measurements between groups
were evaluated by ANOVA test with post hoc Bonfer-
roni correction.
Sensitivity, specificity, accuracy, negative predictive
value (NPV), and positive predictive value (PPV) of vis-
ual analysis of NM-MRI for distinguishing PD2_5y from
non-PD (MSA-P and HC) were calculated using a contin-
gency table. “Probable PD” or “Possible PD” classifications
were merged into the classification “PD”. Classifications of
“uncertain” were considered false positives when attrib-
uted to MSA-P or HC and false negatives when attributed
to PD2_5y.
Discriminative ability of quantitative methods of SN NM-
MRI was evaluated by calculating the Receiver Operating
Characteristic (ROC) curve and the area under the curve
(AUC) for each group and each quantitative analysis.
A p-value of 0.05 was considered significant.
All analyses were performed with the IBM SPSS soft-
ware version 24.
Results
Demographic and clinical characteristics of MSA-P,
PD2_5y, and HC
The study included 30 patients with MSA-P, 10 PD2_5y
and 10 HC. Table 1 shows the demographic and clinical
characteristics of the participants at the time of MRI.
There were no differences in sex or age distribution
between the groups (p = 0.077, p = 0.161, respectively).
MSA-P and PD patients had the same disease duration.
LEDD was not different but HY stage was higher in
MSA-P (2.5 ± 0.5 vs. 2.0 ± 0.0, p < 0.001).
Simple visual analysis of SN and LC in MSA-P patients
Neuromelanin visual analysis
SN size was normal in 69% (20/29). Of those with re-
duced SN size, the reduction was symmetrical in 5/9
and the lateral SN segment was the most affected (7/9)
(Fig. 1.1, additional Table 1). The SN signal intensity was
normal in 69% (20/29) (Fig. 2.2, Fig. 3a). None had ab-
sent SN signal. The proportion of patients with criteria
for possible vs. probable MSA was similar in those with
reduced SN size/signal intensity and those with normal
SN (p = 0.872/p = 0.438).
LC signal intensity was normal in 61% (17/28). In patients
with reduced/absent LC signal, the reduction was bilateral
in 54% (6/11) (Fig. 2.3, Fig. 3d, additional Table 1).
Thirteen patients (43%) had normal visual analysis of
both SN and LC; five patients (17%) had abnormal SN
and LC (size or signal intensity); six patients (20%) had
normal SN size/signal intensity but abnormal LC, and
four patients (13%) had abnormal SN size/signal inten-
sity and normal LC. Of the eight patients classified as
probable MSA-P, visual analysis showed that none had
abnormal LC and four had both normal SN and LC. The
HY stage tended to be more severe (2.8 ± 0.6) in patients
with both normal SN and LC NM visual analysis and less
severe in those with abnormal analysis of both structures
(2.0 ± 0.0) (p = 0.081). These subgroups were not different
in age (p = 0.580), time from first symptom (p = 0.453),
time from diagnosis (p = 0.467) or LEDD (p = 0.240).
Nigrosome-1 visual analysis
N1 visual analysis of MSA-P patients is shown in Fig. 2.4
and additional Table 1. Patients with N1 loss (14/19)
and without N1 loss (5/19) were not different in SN size,
SN signal intensity or LC signal intensity (p = 0–637,
p = 0.709, p = 0.459). Of the five MSA-P patients with
N1 signal, two had normal NM visual analysis.
Disease duration since diagnosis, HY stage and LEDD,
were similar in patients with N1 and those with N1 loss
(p = 0.610, p = 0.608, p = 0.804, p = 0.725, respectively).
Comparison of visual analysis in the three groups
Comparison of neuromelanin visual analysis in MSA-P,
PD2_5y, and HC
Additional Table 1 presents the results of visual analysis
in PD2_5y and HC groups. The visual pattern of SN and
LC in NM-MRI was different in MSA-P vs. PD2_5y and
in PD2_5y vs. HC, but was similar in MSA-P and HC
(Fig. 3, Fig. 4).
Ability of visual analysis of NM-MRI to discriminate between
PD and non-PD
The SN NM-MRI visual pattern was classified as sug-
gestive of PD (probable or possible) vs. not suggestive of
PD vs. uncertain, for each subject (Fig. 5).
The visual pattern of SN in NM-MRI suggesting PD,
had a sensitivity of 90%, specificity of 81%, accuracy of
83%, NPV of 98%, and PPV of 50% for the diagnosis of
PD and to distinguish PD from MSA and HC.
Morphometrics
Middle cerebellar peduncle width in sagittal T1, pons/mid-
brain ratio, parkinsonian index and parkinsonism index
version 2.0 were able to discriminate MSA-P from PD2_5y
and HC, but not PD2_5y from HC (additional Table 2).
Semi-automated imaging analysis
Additional Table 1 shows the semi-automated measure-
ments in the three groups.
Comparing the visual rates of SN size with the SN area
measured by semi-automated methods, for each individ-
ual SN, no differences were found between those
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considered having normal size vs. reduced size by visual
inspection (28.7 ± 10.8 vs. 26.2 ± 10.2, p = 0.333). CR in
the internal SN, for each individual SN, tended to be
lower in participants who had reduced SN intensity sig-
nal by visual inspection (1.1 ± 0.1 vs. 1.2 ± 0.0, p = 0.052);
but CR in the lateral SN was similar in participants with
normal and abnormal SN signal visual inspection (1.1 ±
0.0 vs. 1.1 ± 0.1, p = 0.185).
Comparison of quantitative analysis in the three groups
Comparison of quantitative analysis of SN NM in MSA-P,
PD2_5y and HC
SN semi-automated area was statistically different be-
tween the diseased groups and HC, but did not differ be-
tween PD2_5y and MSA-P (additional Table 1).
In contrast, mean CR of the internal and external SN
segments were different in PD2_5y and MSA-P (add-
itional Table 1). But mean CR of the SN internal seg-
ment did not distinguish PD2_5y or MSA-P from HC.
Mean CR of the SN external segment was also similar in
HC and MSA-P (additional Table 1). Left and right SN
values for each parameter, measured by the asymmetry
index, did not differ between groups (additional Table
1).
Ability of quantitative analysis of SN NM-MRI to
discriminate between PD and non-PD
Figure 6 shows the ROC curves and AUC considering
SN mean area and mean CR of both lateral and internal
segments to discriminate each group from the others.
None of these parameters had good discriminatory abil-
ity for distinguishing PD from MSA-P or HC.
CR of both lateral and internal SN segments seems to
be able to discriminate MSA-P from HC and PD2_5y
(AUC = 0.71, AUC = 0.82). The mean SN area discrimi-
nates HC from diseased groups with high sensitivity and
specificity (AUC = 0.97).
Discussion
This is the first study to use simple visual analysis of
NM-MRI in patients with MSA-P. Most MSA-P patients
diagnosed according to the gold standard second con-
sensus clinical criteria [1], had normal SN size and signal
intensity, and normal LC signal. This pattern was clearly
distinct from the findings in PD patients with similar
disease duration, and overlapped with the healthy con-
trols. Loss of nigrosome-1 in SWI sequences, a patho-
logical hallmark of neurodegeneration, may help to
distinguish MSA-P from healthy controls.
SN and LC NM-MRI have been extensively studied in
patients with PD, mostly using quantitative measure-
ments (volume, area, width, CR) [8–11]. Qualitative vis-
ual analysis of NM SN and LC is an easy and fast
imaging evaluation method, without the need for post-
Fig. 2 Visual analysis of SN and LC in NM-MRI and nigrosome-1 in
SWI in patients with MSA-P
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Fig. 3 Neuromelanin-sensitive MRI axial images of SN (a-c) and LC (d-f) in a patient with MSA-P (a, d), PD with 2–5 years of duration (b, e) and a
healthy control (c, f)
Fig. 4 Comparison of the visual pattern of SN size, SN signal intensity and LC signal intensity in NM-MRI, in MSA-P, PD 2–5 years of duration and
healthy controls
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processing software, and was recently shown to have
similar diagnostic accuracy to more time consuming
quantitative methods [10–12]. In our study, and in
agreement with previous studies using qualitative visual
analysis, the majority of PD patients had a unilateral de-
crease of the SN size and signal intensity (90–100%),
mostly affecting the lateral region, and a bilateral reduc-
tion of LC signal (90%) [6–12, 21].
None of the previous studies analyzing NM-MRI in
MSA-P [18–20] used visual analysis of the SN or LC.
Two studies measured the SN CR [18, 19] and one used
the SN volume [20]. In these studies, the results did not
differentiate PD from MSA, but the SN CR and SN vol-
ume were smaller in MSA than in controls [18, 20]. This
contrasts with our findings in that the NM CR on the
lateral and internal SN segments discriminated between
MSA-P and PD. Additionally, the quantitative measure-
ments of the SN signal intensity in our study mirror and
support the findings of NM visual inspection of the SN.
We found a normal LC signal in 59% of MSA patients.
When considering only MSA-P patients fulfilling criteria
for probable MSA, all had normal LC signal intensity,
suggesting a higher specificity of this finding. Previous
findings related to LC CR were contradictory [18, 20].
Small (9 and 10 patients) [18, 19] and/or heterogeneous
MSA samples (different MSA subtypes included) [19,
20] in previous studies may explain these discrepancies.
A volumetric study that included a larger group of 28
MSA patients who had similar disease duration to our
patient group (3.9 ± 2 years) was unable to find signifi-
cant differences between PD and MSA [19]. The data
presented by this group is not clear when it comes to
MSA clinical subtype and since it is a Japanese study,
where there is a higher prevalence of MSA-C [27], this
group is probably not comparable to ours which specif-
ically excludes MSA-C patients.
The most frequent MSA-P NM visual pattern in our
study overlapped with that of normal controls. Although
the loss of SN NM has been considered a biomarker of
nigral degeneration in PD [6], most of our MSA-P pa-
tients had normal SN NM by visual inspection, despite a
well-known presynaptic dopaminergic dysfunction.
Postmortem NM-MRI studies have shown that SN NM
is directly related to the number of NM-containing neu-
rons [28] and that degenerated neurons may still contain
NM granules so that SN NM measurements may not re-
flect dopaminergic function [29]. This may explain the
apparent dissociation between dopamine transporter im-
aging, which measures dopaminergic function [30] or
dopamine levels [31], and NM-MRI in MSA-P.
In our MSA-P patients, the clue to nigral pathology
was the loss of N1, usually bilaterally, which was de-
scribed in 74%. Although SWI sequences were not avail-
able for analysis in HC, loss of N1 has been previously
described as pathological and a hallmark of nigral degen-
eration [17]. Our results are supported by those reported
by Reiter et al. who included a substantial number of
MSA patients (n = 22) and found N1 loss in SWI 3 T
MRI in all, being able to discriminate between MSA and
HC with a 100% sensitivity and 97% specificity [17]. In
this same study, loss of the “swallow-tail-sign” helped to
diagnose degenerative parkinsonism, regardless of noso-
logical entity, versus HC, with a sensitivity of 94% and
specificity of 90% [17]. In our study, N1 loss analysis was
not available for PD or HC. However, previous results
strongly suggest that N1 loss is pathological and that
healthy subjects have a preserved N1. Extrapolating this
knowledge to our HC sample, we would expect that,
Fig. 5 Classification of NM-MRI visual SN pattern in each group according to the radiological diagnosis of PD (probable PD, possible PD, not
suggestive of PD and uncertain)
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although the NM pattern would be similar (not de-
creased in size or signal intensity) in both MSA-P and
HC, the N1 loss in diseased subjects would help to set
apart these two groups only based in MRI visual
analysis.
Nigral degeneration in MSA-P is corroborated in our
study by N1 loss, but it occurs without significant NM
loss, by visual analysis. This contrasts to what has been
described for PD in which there is both SN NM
reduction (as also corroborated in our study) and N1
loss. Reimão et al. (2016) have shown that there is no
technical interference of iron paramagnetic properties in
the SN NM MRI signal, and the same study also sug-
gested that NM loss and N1 loss in PD were independ-
ent mechanisms [32]. Our findings in MSA-P,
dissociating NM and N1 signals, also support the hy-
pothesis that iron deposition and NM loss may be dis-
tinct and independent pathophysiological mechanisms.
Fig. 6 Ability of quantitative methods to discriminate between MSA-P, PD2_5y and HC, evaluated by ROC curves
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Also, the distinct NM and N1 signals in MSA-P and
PD, may suggest that nigral dysfunction in these disor-
ders would result from different mechanisms. Both are
synucleinopathies, but α-synuclein aggregates have a dis-
tinct distribution, mostly affecting the dopaminergic
neurons in PD and the olygodendrocytes in MSA. From
our findings, one could expect that dopaminergic neur-
onal loss would be less pronounced in MSA than in PD
and/or that remaining dopaminergic neurons in MSA
would lose less NM than those in PD. Post mortem
neuropathological studies in MSA do not corroborate
our first hypothesis as severe duration-dependent neur-
onal loss in SN is described [2]. However, in these post
mortem samples, few early-stage MSA patients were in-
cluded (median disease duration of 7.3 years) [2, 5]. Sup-
porting the second hypothesis, α-synuclein has been
shown to inhibit melanin synthesis in dopaminergic neu-
rons, lowering intracellular melanin content [33]. As
neuronal α-synuclein inclusions predominate in PD, one
may hypothesize that NM loss would be accelerated and
consequently more severe in PD than MSA-P, for the
same disease stage. This could justify the preserved vis-
ual inspection of SN and LC NM in most of our early
patients in the present study. Decreasing SN signal and
area with disease progression and severity has been de-
scribed in PD [22, 34], and may also occur in MSA-P.
However, in our study, a third of MSA-P had decreased
SN size/signal intensity, mostly bilateral, but this sub-
group was not clinically different from those with nor-
mal SN, therefore distinct disease stages do not explain
these findings. Studies on MSA-P patients in different
disease stages would be necessary to confirm this
hypothesis.
Visual inspection of NM-MRI sequences seems to be
more reliable to differentiate PD from MSA-P than
quantitative measurements. In our study, visual inspec-
tion of NM in what relates to SN size, signal intensity
and asymmetry can distinguish PD from MSA and HC
with a sensitivity of 90% and a specificity of 80%. Quan-
titative SN area and CR of lateral and medial SN seg-
ments were not able to discriminate PD from MSA and
HC. The AUC suggests that the mean SN area is able to
discriminate healthy subjects from diseased patients with
high sensitivity and specificity and the CR may distin-
guish MSA from healthy subjects and PD with moderate
sensitivity and specificity.
However, although lateral and medial SN CRs were statis-
tically different in MSA and PD, the time consuming method
and the unavailability of a cut-off for this discrimination
needs to be addressed in the future to allow it’s usage in clin-
ical practice. Also, sensitivity and specificity seem to be lower
than when using visual inspection of SN NM-MRI.
The inability of quantitative semi-automated measure-
ments to discriminate between PD and MSA may be
explained by the technique. These methods with region
growing algorithms use a seeding point in a given region
of interest (ROI) and compare it with adjacent areas.
When there is a diffuse reduction in NM T1 high inten-
sity signal in the SN, when placing the ROI, there will be
no significant difference between neighboring pixels, and
the automated methods will not be able to calculate the
SN area/signal nor detect specific pattern changes. By
contrast, visual analysis is able to detect the specific pat-
tern of asymmetrical size and signal intensity reduction
typical of PD that is not present in most MSA-P pa-
tients, leading to higher discriminatory ability than
quantitative methods.
The major strengths of our study are the large and
homogenous sample of MSA-P patients, the devoted
movement disorders MRI protocol that was used and the
previous experience of our neuroradiologist in visual rat-
ing of SN and LC in NM-MRI. However, in our MSA-P
sample, only a small subset fulfilled second consensus cri-
teria for probable MSA. The short disease duration of our
patients (median from first symptom of 4 years and me-
dian time from diagnosis of 1 year), may prevent a full-
blown clinical picture, decreasing the level of certainty for
diagnosis. Additionally, we cannot exclude misdiagnosis in
our MSA sample. In our study, a third of MSA-P had de-
creased SN area/signal intensity and this was mostly bilat-
eral. Of these, in only 2/9, the combined analysis was
suggestive of possible PD. The MSA diagnostic criteria
have been criticized for having suboptimal diagnostic ac-
curacy [35]. The tendency for MSA-P patients with abnor-
mal LC and/or SN pattern to have a lower HY stage could
suggest that these patients may have been wrongly diag-
nosed as MSA-P and corresponded in fact to PD.
Additionally, historic controls were used for compari-
son with our MSA-P patients. Although we tried to con-
trol for age, disease duration and LEDD in both diseased
groups, the HY stage was statistically different. The
higher HY in MSA-P was somehow expected, as MSA-P
is a more severe disorder with less benefit from dopa-
minergic medication. Both disease duration [34] and dis-
ease severity measured by the HY [22] have been
previously reported to correlate with reduced SN neuro-
melanin in PD. However, conclusions cannot be dropped
for HY stage effect in NM SN signal in MSA-P patients
as it seems that in these patients NM has a distinct be-
havior from PD. In fact, in our study, most MSA-P pa-
tients have normal SN NM size and signal intensity by
visual inspection besides a higher HY, which was the op-
posite one would expect by the NM behavior in PD. The
effect of this difference in these two groups is unknown
and was controlled during statistical analysis.
An additional weakness was the unavailability of the
SWI sequences for historic controls for comparison with
MSA-P patients.
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Also, simple visual analysis is an observer-dependent
analysis. However, this would be minimized by expert
reading of the images. Having had individual raters to
perform the visual analysis and comparing the inter-
rater agreement would have supported the validity of
our results. Despite not having this double rating in our
study, our group has previously published a simple visual
inspection of SN neuromelanin images, read by individ-
ual raters, in which Cohen’s Kappa Coefficient showed
fair to moderate inter-rater agreement (0.39 for SN sig-
nal/size, 0.45 for subject classification), supporting the
validity of our qualitative results [11].
Future studies of combined visual analysis of the NM
and N1 loss in patients with parkinsonism, with larger
samples of clinically homogenous subtypes, will improve
our understanding of the neuroimaging characteristics of
these conditions. It would also be of interest to evaluate
MSA-C and adult-onset spinocerebellar ataxias NM and
N1 imaging findings.
Conclusions
Our findings suggest that simple visual inspection of
NM in the SN and LC may easily distinguish PD from
MSA-P patients, even in early stages. PD patients have a
specific imaging pattern that contrasts with a normal
NM pattern in the majority of MSA-P patients. In our
study, the presence of decreased unilateral SN and LC
NM pattern was strongly suggestive of PD and excluded
the diagnosis of MSA-P with a sensitivity of 90%, specifi-
city of 81%, and accuracy of 83%. Combined visual in-
spection of NM-MRI and N1 in SWI is suggested to set
apart non-PD degenerative parkinsonism from healthy
subjects.
Experienced neuroradiologists can use these not time
consuming and widely available imaging techniques to
greatly help clinical evaluation of individual patients with
parkinsonism.
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